Interviews

“Four or five major acquisitions over the last few years repositioned it, a 140-year-old company, from being a B-to-B company to B-to B-to-C company. That is a major enterprise strategy shift,” says CEO Patrick Lockwood-Taylor.

Chugai’s partnering office in South San Francisco advances the Japanese company’s business development activities in the US beyond its venture fund established in Boston in 2023.

Teva’s R&D chief Eric Hughes discusses the company’s long-acting injectable olanzapine program, how it could address adherence challenges in schizophrenia, and why the therapy forms a key pillar of the firm’s growing injectables franchise.

In an interview with Scrip, Samsung Bioepis’ VP and Innovation Project Lead talks about the newly launched innovation project as well as the firm's strategies and goals in ADCs and other novel therapeutics.

After nearly 30 years at NASA, Omar Hatamleh prepares for his next chapter and fourth book on AI. He told Medtech Insight AI will speed up medical breakthroughs, extend life spans and bring AGI sooner than expected but also drive job losses, erode privacy and force humans to rethink their purpose.

When OSE Immunotherapeutics' board ousted CEO Nicolas Poirier in October 2025, it handed his successor a clear mandate: spend less, partner sooner and stop asking shareholders to wait.

Renée Aguiar-Lucander, CEO of Hansa Biopharma, discussed the company’s leading asset, its journey toward US FDA approval and the trials and tribulations of completing a Phase III program.

Boehringer Ingelheim is restructuring its therapeutic operations to push decision-making closer to brand teams while keeping R&D spending around 25% of revenues.

Biogen’s president and head of North America talked to Scrip about the company’s commercial expansion into new areas in immunology and nephrology.

The pharma titan candidly speaks about the M&A landscape, high R&D costs and the potential of AI as the industry gets set to navigate a host of existing and new challenges.

“Our sense is that companies are currently focused on timing, scope and execution. For example, knowing when a final order might issue … We also imagine that formulators are scrutinizing the proposed list of permitted combinations, the 6% cap, and the permitted dosage forms,” say ArentFox Schiff att

From biotech experiments to billion-dollar breakthroughs, Noubar Afeyan has built a career out of turning bold ideas into transformative companies.